<DOC>
	<DOCNO>NCT02941601</DOCNO>
	<brief_summary>The main purpose study evaluate effectiveness safety gemcitabine-carboplatin plus necitumumab chemotherapy-naïve participant locally advance metastatic squamous non-small cell lung cancer .</brief_summary>
	<brief_title>A Study Gemcitabine-Carboplatin Plus Necitumumab ( LY3012211 ) Chemotherapy-Naïve Participants With Locally Advanced Metastatic Squamous Non-Small Cell Lung Cancer ( NSCLC )</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Have confirm diagnosis locally advance metastatic NSCLC Cohort 1 metastatic NSCLC Cohort 2 , predominantly squamous histology . Squamous NSCLC diagnosis must confirm histology cytology local pathology report . Participants Cohort 1 require epidermal growth factor receptor ( EGFR ) protein express tumor ( defined local immunohistochemistry test ) . This required participant Cohort 2 . Measurable disease time study entry define Response Evaluation Criteria Solid Tumors Version 1.1 ( RECIST 1.1 ) The participant Eastern Cooperative Oncology Group performance status ( ECOG PS ) score 01 Have discontinue previous treatment cancer recover acute effect therapy : Biologic agent ( example , antibody ) Immunotherapy ≥4 week ; Chest radiotherapy ≥4 week ; Major surgery , exclude biopsy ≥4 week ) The participant archive tumor tissue available biomarker analysis . Participants Cohort 2 require receive 1 prior singleagent immune checkpoint inhibitor squamous NSCLC . The participant nonsquamous NSCLC The participant receive prior anticancer therapy target EGFR , vascular endothelial growth factor ( VEGF ) , VEGF receptor . The participant receive previous chemotherapy ( include concurrent chemoradiation ) advance NSCLC ( participant receive neoadjuvant and/or adjuvant chemotherapy eligible last administration occur least 1 year prior start therapy ) . The participant brain metastasis symptomatic require ongoing treatment steroid anticonvulsant . The participant bleeding tumor . The participant history arterial venous thromboembolism within 3 month prior study enrollment . The participant history evidence current clinicallyrelevant coronary artery disease current ≥ Class III define Canadian Cardiovascular Society Angina Grading Scale ( Campeau 1976 ) congestive heart failure current ≥ Class III define New York Heart Association . The participant experience myocardial infarction within 6 month prior study enrollment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Thoracic Neoplasms</keyword>
	<keyword>Lung Diseases</keyword>
	<keyword>Lung Cancer</keyword>
	<keyword>Respiratory Tract Diseases</keyword>
	<keyword>Respiratory Tract Neoplasms</keyword>
	<keyword>Antineoplastic Agents</keyword>
	<keyword>Monoclonal Antibodies</keyword>
</DOC>